Mucosal immune features to phosphorylcholine by nasal Flt3 ligand cDNA-based vaccination
Authors:
- Kosuke KataokaKKKosuke Kataoka
- Masaki GotoMGMasaki Goto
- 1 August 2011
- Vol. 29 (34) , 5747-5757
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- A Combination of Flt3 Ligand cDNA and CpG Oligodeoxynucleotide as Nasal Adjuvant Elicits Protective Secretory-IgA Immunity to Streptococcus pneumoniae in Aged MiceThe Journal of Immunology, 2011
- Secretory-IgA Antibodies Play an Important Role in the Immunity to Streptococcus pneumoniaeThe Journal of Immunology, 2010
- Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthraxProceedings of the National Academy of Sciences, 2010
- Fusobacterium nucleatumEnvelope Protein FomA Is Immunogenic and Binds to the Salivary Statherin-Derived PeptideInfection and Immunity, 2010
- Natural Antibodies against Phosphorylcholine in Cardiovascular DiseaseAnnals of the New York Academy of Sciences, 2009
- Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccinesExpert Review of Vaccines, 2009
- A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunityVaccine, 2008
- Intranasal immunization with phosphorylcholine induces antigen specific mucosal and systemic immune responses in miceVaccine, 2007
- Phosphorylcholine: friend or foe of the immune system?Immunology Today, 1999
- Monoclonal vs. heterogeneous anti‐H‐8 antibodies in the analysis of the anti‐phosphorylcholine response in BALB/c miceEuropean Journal of Immunology, 1981